2026 Q2 - tulosraportti
68 päivää sitten
‧52 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 641 | DCAR | DCAR | ||
| 177 | - | - | ||
| 91 | - | - | ||
| 266 | - | - | ||
| 504 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 16.7. | ||
2026 Q1 - tulosraportti 22.4. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 23.10.2025 | ||
2025 Q2 - tulosraportti 15.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
1 päivä sittennice forward leaning press release fro the company about the EBJIS conference. Sounds pretty positive and even an award to the scientist behind SOLARIO
NEJM/SOLARIO → increased scientific acceptance → EBJIS exposure to hundreds of specialists in orthopedic infections → more clinics gain experience with CERAMENT → higher American reimbursement → potentially faster adoption.- 17.9.So we have cms reimbursement out -old news but mentioned by mgmt as driver Solario study out the other big driver that can drive better sales It should give us more firm line of sight for fy guidance Have to admit im surprised to see stock only moves 1% on this news, u would expect a break out from trading range
·16.9.Ran today's article in Financial Times about Bonesupport and the highest short interest, through Gemini; The article highlights the ongoing conflict between Bonesupport's strong commercial growth and an extensive short-selling wave driven by doubts surrounding the mechanism of action of antibiotic release. Key points in the FT article Commercial Strength vs. Short-Selling Paradox: Bonesupport guides for organic growth of 33–36%, has only buy recommendations from the analysis firm and lacks financial capital needs. Despite this, the stock is one of Europe's most shorted (~27 trading days' turnover to cover the positions). Short sellers' thesis: A Danish study published in the Journal of Bone and Joint Surgery claims that Cerament's 28-day antibiotic release is based on flawed experimental design (serial dilution) and that >99% of the antibiotic is actually released within 24 hours in mouse models. Bonesupport's defense: The mouse model placed the material in soft tissue without the containment and bone contact crucial for clinical function. The company relies on human data from over 340 clinical studies on more than 3,000 patients. Short-term catalysts: The FDA decision regarding Cerament V (where additional biocompatibility data was recently requested) and the results from the large-scale SOLARIO study at Oxford University. Impact on Bonesupport as an Investment Case 1. The Scientific Case: Human In-Vivo vs. Mouse Models Clinical evidence carries more weight: In orthobiologics, actual clinical results in humans (real-world evidence) have far higher evidentiary value than academic mouse models in soft tissue. With over 12,000 annual procedures in the USA alone and a strong repurchase frequency among orthopedic surgeons, commercial acceptance is practical proof of function. Conflict of interest among critics: The authors behind the Danish study are founders of Precision Antibiotics (funded by Novo Nordisk Fonden), a startup company developing a directly competing local antibiotic delivery. The short-selling narrative is thus based on criticism from a commercial challenger. 2. Catalysts and Volatility Drivers The SOLARIO study as a commercial lever: Demonstrating that local antibiotics enable a shortening of the systemic antibiotic course (from ≥ 4 weeks to ≤ 7 days) strengthens the health economic argument towards hospitals and insurance systems (CMS/Medicare). FDA & Cerament V: The delay in the FDA decision creates a short-term regulatory overhang. Since the Cerament platform is already approved in the USA (Cerament G) and Cerament V has been approved in the EU since 2015, the delay appears more as a matter of documentation timing than a fundamental product risk. Strong Squeeze Potential: With short positions equivalent to approximately 27 trading days, any news that removes doubt (e.g., a positive outcome from the FDA or strong quarterly reports) can trigger a rapid and powerful short squeeze. 3. Risks to Monitor Short-term uncertainty among surgeons: Even if the theoretical criticism is weak in a clinical context, academic debate and newspaper headlines can create temporary hesitation among cautious orthopedic surgeons regarding product choice. Protracted timeline in the USA: If the FDA process for Cerament V is further prolonged, it could temporarily pressure the valuation multiple, even if the core business of Cerament G continues to grow strongly. The FT article points to a classic conflict between theoretical pre-clinical criticism and proven clinical and commercial execution. For a long-term investor, the short sellers' thesis appears exaggerated as it is based on mouse models outside bone tissue rather than the extensive human data underlying the company's approvals. The high short interest creates short-term price volatility but also offers significant upside if the company continues to deliver on its financial goals.
I want to emphasize that theses put forward by a competitor should be taken for the interests the competitor represents. Bonexx's preparation is intended for bones, not soft tissues. Short sellers also place articles and their own analyses with the intention of lowering the share price. Bonex has strong reports and a management that continues to own and buy shares. 8 different banks/brokers all set buy, no neutral and no sell. Just last week, SEB set buy with 130 kr as target price. I believe more in facts than in those who have their own interests in lowering the share price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 994 | 339 994 | 0 | 0 |
| Avanza Bank AB | 3 500 | 3 500 | 0 | 3 500 |
| DCAR | 641 | 641 | 0 | 641 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 994 | 339 994 | 0 | 0 |
| Avanza Bank AB | 3 500 | 3 500 | 0 | 3 500 |
| DCAR | 641 | 641 | 0 | 641 |
2026 Q2 - tulosraportti
68 päivää sitten
‧52 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 1 päivä sittennice forward leaning press release fro the company about the EBJIS conference. Sounds pretty positive and even an award to the scientist behind SOLARIONEJM/SOLARIO → increased scientific acceptance → EBJIS exposure to hundreds of specialists in orthopedic infections → more clinics gain experience with CERAMENT → higher American reimbursement → potentially faster adoption.
- 17.9.So we have cms reimbursement out -old news but mentioned by mgmt as driver Solario study out the other big driver that can drive better sales It should give us more firm line of sight for fy guidance Have to admit im surprised to see stock only moves 1% on this news, u would expect a break out from trading range
- ·16.9.Ran today's article in Financial Times about Bonesupport and the highest short interest, through Gemini; The article highlights the ongoing conflict between Bonesupport's strong commercial growth and an extensive short-selling wave driven by doubts surrounding the mechanism of action of antibiotic release. Key points in the FT article Commercial Strength vs. Short-Selling Paradox: Bonesupport guides for organic growth of 33–36%, has only buy recommendations from the analysis firm and lacks financial capital needs. Despite this, the stock is one of Europe's most shorted (~27 trading days' turnover to cover the positions). Short sellers' thesis: A Danish study published in the Journal of Bone and Joint Surgery claims that Cerament's 28-day antibiotic release is based on flawed experimental design (serial dilution) and that >99% of the antibiotic is actually released within 24 hours in mouse models. Bonesupport's defense: The mouse model placed the material in soft tissue without the containment and bone contact crucial for clinical function. The company relies on human data from over 340 clinical studies on more than 3,000 patients. Short-term catalysts: The FDA decision regarding Cerament V (where additional biocompatibility data was recently requested) and the results from the large-scale SOLARIO study at Oxford University. Impact on Bonesupport as an Investment Case 1. The Scientific Case: Human In-Vivo vs. Mouse Models Clinical evidence carries more weight: In orthobiologics, actual clinical results in humans (real-world evidence) have far higher evidentiary value than academic mouse models in soft tissue. With over 12,000 annual procedures in the USA alone and a strong repurchase frequency among orthopedic surgeons, commercial acceptance is practical proof of function. Conflict of interest among critics: The authors behind the Danish study are founders of Precision Antibiotics (funded by Novo Nordisk Fonden), a startup company developing a directly competing local antibiotic delivery. The short-selling narrative is thus based on criticism from a commercial challenger. 2. Catalysts and Volatility Drivers The SOLARIO study as a commercial lever: Demonstrating that local antibiotics enable a shortening of the systemic antibiotic course (from ≥ 4 weeks to ≤ 7 days) strengthens the health economic argument towards hospitals and insurance systems (CMS/Medicare). FDA & Cerament V: The delay in the FDA decision creates a short-term regulatory overhang. Since the Cerament platform is already approved in the USA (Cerament G) and Cerament V has been approved in the EU since 2015, the delay appears more as a matter of documentation timing than a fundamental product risk. Strong Squeeze Potential: With short positions equivalent to approximately 27 trading days, any news that removes doubt (e.g., a positive outcome from the FDA or strong quarterly reports) can trigger a rapid and powerful short squeeze. 3. Risks to Monitor Short-term uncertainty among surgeons: Even if the theoretical criticism is weak in a clinical context, academic debate and newspaper headlines can create temporary hesitation among cautious orthopedic surgeons regarding product choice. Protracted timeline in the USA: If the FDA process for Cerament V is further prolonged, it could temporarily pressure the valuation multiple, even if the core business of Cerament G continues to grow strongly. The FT article points to a classic conflict between theoretical pre-clinical criticism and proven clinical and commercial execution. For a long-term investor, the short sellers' thesis appears exaggerated as it is based on mouse models outside bone tissue rather than the extensive human data underlying the company's approvals. The high short interest creates short-term price volatility but also offers significant upside if the company continues to deliver on its financial goals.I want to emphasize that theses put forward by a competitor should be taken for the interests the competitor represents. Bonexx's preparation is intended for bones, not soft tissues. Short sellers also place articles and their own analyses with the intention of lowering the share price. Bonex has strong reports and a management that continues to own and buy shares. 8 different banks/brokers all set buy, no neutral and no sell. Just last week, SEB set buy with 130 kr as target price. I believe more in facts than in those who have their own interests in lowering the share price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 641 | DCAR | DCAR | ||
| 177 | - | - | ||
| 91 | - | - | ||
| 266 | - | - | ||
| 504 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 16.7. | ||
2026 Q1 - tulosraportti 22.4. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 23.10.2025 | ||
2025 Q2 - tulosraportti 15.7.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 994 | 339 994 | 0 | 0 |
| Avanza Bank AB | 3 500 | 3 500 | 0 | 3 500 |
| DCAR | 641 | 641 | 0 | 641 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 994 | 339 994 | 0 | 0 |
| Avanza Bank AB | 3 500 | 3 500 | 0 | 3 500 |
| DCAR | 641 | 641 | 0 | 641 |
2026 Q2 - tulosraportti
68 päivää sitten
‧52 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 16.7. | ||
2026 Q1 - tulosraportti 22.4. | ||
2025 Q4 - tulosraportti 24.2. | ||
2025 Q3 - tulosraportti 23.10.2025 | ||
2025 Q2 - tulosraportti 15.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 1 päivä sittennice forward leaning press release fro the company about the EBJIS conference. Sounds pretty positive and even an award to the scientist behind SOLARIONEJM/SOLARIO → increased scientific acceptance → EBJIS exposure to hundreds of specialists in orthopedic infections → more clinics gain experience with CERAMENT → higher American reimbursement → potentially faster adoption.
- 17.9.So we have cms reimbursement out -old news but mentioned by mgmt as driver Solario study out the other big driver that can drive better sales It should give us more firm line of sight for fy guidance Have to admit im surprised to see stock only moves 1% on this news, u would expect a break out from trading range
- ·16.9.Ran today's article in Financial Times about Bonesupport and the highest short interest, through Gemini; The article highlights the ongoing conflict between Bonesupport's strong commercial growth and an extensive short-selling wave driven by doubts surrounding the mechanism of action of antibiotic release. Key points in the FT article Commercial Strength vs. Short-Selling Paradox: Bonesupport guides for organic growth of 33–36%, has only buy recommendations from the analysis firm and lacks financial capital needs. Despite this, the stock is one of Europe's most shorted (~27 trading days' turnover to cover the positions). Short sellers' thesis: A Danish study published in the Journal of Bone and Joint Surgery claims that Cerament's 28-day antibiotic release is based on flawed experimental design (serial dilution) and that >99% of the antibiotic is actually released within 24 hours in mouse models. Bonesupport's defense: The mouse model placed the material in soft tissue without the containment and bone contact crucial for clinical function. The company relies on human data from over 340 clinical studies on more than 3,000 patients. Short-term catalysts: The FDA decision regarding Cerament V (where additional biocompatibility data was recently requested) and the results from the large-scale SOLARIO study at Oxford University. Impact on Bonesupport as an Investment Case 1. The Scientific Case: Human In-Vivo vs. Mouse Models Clinical evidence carries more weight: In orthobiologics, actual clinical results in humans (real-world evidence) have far higher evidentiary value than academic mouse models in soft tissue. With over 12,000 annual procedures in the USA alone and a strong repurchase frequency among orthopedic surgeons, commercial acceptance is practical proof of function. Conflict of interest among critics: The authors behind the Danish study are founders of Precision Antibiotics (funded by Novo Nordisk Fonden), a startup company developing a directly competing local antibiotic delivery. The short-selling narrative is thus based on criticism from a commercial challenger. 2. Catalysts and Volatility Drivers The SOLARIO study as a commercial lever: Demonstrating that local antibiotics enable a shortening of the systemic antibiotic course (from ≥ 4 weeks to ≤ 7 days) strengthens the health economic argument towards hospitals and insurance systems (CMS/Medicare). FDA & Cerament V: The delay in the FDA decision creates a short-term regulatory overhang. Since the Cerament platform is already approved in the USA (Cerament G) and Cerament V has been approved in the EU since 2015, the delay appears more as a matter of documentation timing than a fundamental product risk. Strong Squeeze Potential: With short positions equivalent to approximately 27 trading days, any news that removes doubt (e.g., a positive outcome from the FDA or strong quarterly reports) can trigger a rapid and powerful short squeeze. 3. Risks to Monitor Short-term uncertainty among surgeons: Even if the theoretical criticism is weak in a clinical context, academic debate and newspaper headlines can create temporary hesitation among cautious orthopedic surgeons regarding product choice. Protracted timeline in the USA: If the FDA process for Cerament V is further prolonged, it could temporarily pressure the valuation multiple, even if the core business of Cerament G continues to grow strongly. The FT article points to a classic conflict between theoretical pre-clinical criticism and proven clinical and commercial execution. For a long-term investor, the short sellers' thesis appears exaggerated as it is based on mouse models outside bone tissue rather than the extensive human data underlying the company's approvals. The high short interest creates short-term price volatility but also offers significant upside if the company continues to deliver on its financial goals.I want to emphasize that theses put forward by a competitor should be taken for the interests the competitor represents. Bonexx's preparation is intended for bones, not soft tissues. Short sellers also place articles and their own analyses with the intention of lowering the share price. Bonex has strong reports and a management that continues to own and buy shares. 8 different banks/brokers all set buy, no neutral and no sell. Just last week, SEB set buy with 130 kr as target price. I believe more in facts than in those who have their own interests in lowering the share price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 641 | DCAR | DCAR | ||
| 177 | - | - | ||
| 91 | - | - | ||
| 266 | - | - | ||
| 504 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 994 | 339 994 | 0 | 0 |
| Avanza Bank AB | 3 500 | 3 500 | 0 | 3 500 |
| DCAR | 641 | 641 | 0 | 641 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 994 | 339 994 | 0 | 0 |
| Avanza Bank AB | 3 500 | 3 500 | 0 | 3 500 |
| DCAR | 641 | 641 | 0 | 641 |